See the list below: Medical care for meningiomas has been disappointing. It is restricted either to perioperative drugsor to medications that are used after all other means of treatment have failed. [23] The use of corticosteroids preoperativel and postoperativel has significantl decreased the mortalit and morbidit rates associated with surgical resection. !ntiepileptic drugs should be started preoperativel in supratentorial surger and continued postoperativel for no less than 3 months. The current e"perience with chemotherap is disappointing.o This modalit of treatment is reserved for malignant cases after failure of surger and radiotherap to control the disease.o The main drugs studied include temo#olomide$ which had no effect against recurrent meningiomas in a phase 2 stud[2%] $ and hdro"urea &ribonucleotide reductase inhibitor'( )*+%,- &snthetic antiprogestin'( and interferon+alpha. The last 3 drugs also showed disappointing results. ! recentl published prospective phase 2 stud of irinotecan &./T+00' also failed to demonstrate an efficac.o The combination of interferon alpha and 1+fluorouracil snergisticall reduces meningioma cell proliferation in culture and warrants further investigation.o Some studies have shown a possible role of .23+2 inhibitors in the treatment of recurrent meningiomas.[,]o The role of targeted chemotherap to bloc4 the tumorogenic pathwas of meningiomas atspecific sites is being e"tensivel investigated.[21]o Molecules to bloc4 specific growth factors or en#mes are being developed. !tpical meningioma &562 grade II' and anaplastic meningioma &562 grade III' showed increased fatt acid snthase &7!S' e"pression. 7!S inhibitor &cerulein' decreased meningioma cell survival in vitro. Thus$ increased 7!S e"pression in human meningiomas represents a novel therapeutic target for the treatment of unresectable or malignant meningiomas.[2-] !lthough most meningiomas grow slowl and have a low mitotic rate$ clinical benefit has been reported in man case series with either tumor regression or stasis after radiotherap( however$ these results have not been confirmed in randomi#ed trials. 2a et al reported on the natural histor of meningiomas. [28] The prospect of benign meningioma growth is an important factor to consider in their proper management. !ppro"imatel %9: of 283 meningiomas &in 2%% patients' grew within a %+ear period. ;ac4 of calcification$ hperintensit in T2 M)I$ and peritumoral edema were predictors of growth in follow up. In addition$ age ounger than -9 ears and tumor si#e larger than 21 mm &diameter' were also associated with a greater ris4. )adiotherap is mainl used as ad